BOLT News and Press, Bolt Biotherapeutics Inc. From 04/10/21

REDWOOD CITY, Calif., April 10, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immun...

REDWOOD CITY, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune syst...

Bolt Biotherapeutics (BOLT): Q4 GAAP EPS of -$14.58.Cash, cash equivalents, and marketable securities of $22.8M.Press Release For further details see: Bolt Biotherapeutics reports Q4 results

– Upsized IPO in February 2021 raised $264.5 million in gross proceeds plus Series C raised $93.5 million for a total of $358 million in recent fundraising – – Advanced first-in-class Boltbody ™ ISAC into the clinic in 2020 and continued t...

The following slide deck was published by Bolt Biotherapeutics, Inc. in conjunction with this event. For further details see: Bolt Biotherapeutics (BOLT) Investor Presentation - Slideshow

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead Investors have a variety of events and developments to focus on next week. The impact of the pending FDA approval on Joh...

Two IPOs are scheduled to raise $1.3 billion in the week ahead. Street research is expected for 14 companies. Lock-up periods will be expiring for six companies. For further details see: U.S. IPO Week Ahead: Health Insurer Oscar Health Leads A 2 IPO Week

REDWOOD CITY, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage immuno-oncology company, announced today the closing of its initial public offering of 13,225,000 shares of its common stock, inclusive of the full exercise by the underwriter...